Related Experiment Video

Updated: May 18, 2026

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

Development and strategies of VEGFR-2/KDR inhibitors

Lingyi Huang1, Zhengui Huang, Zhiqiang Bai

  • 1Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, People's Republic of China.

Future Medicinal Chemistry
|October 10, 2012
PubMed

Insights

Small molecule inhibitors targeting VEGFR-2 block key signaling in tumor angiogenesis. Structural analysis guides the development of novel type I and type II drugs with improved activity and selectivity.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Drug Discovery

Background:

  • Vascular Endothelial Growth Factor (VEGF) signaling is crucial for blood vessel formation (angiogenesis).
  • VEGF Receptor 2 (VEGFR-2) is a key mediator of these signals and a primary target for anti-angiogenic cancer therapies.
  • Inhibiting VEGFR-2 autophosphorylation is a critical strategy for blocking tumor growth.

Purpose of the Study:

  • To review the development of small molecule inhibitors targeting VEGFR-2.
  • To analyze structural and conformational insights for optimizing inhibitor design.
  • To discuss strategies for enhancing drug activity, selectivity, and novelty.

Main Methods:

  • Analysis of high-resolution crystal structures of VEGFR-2 inhibitors.
  • Examination of catalytic cleft and DFG motif conformational changes.
  • Structure-activity relationship and binding mode investigations.

Main Results:

  • Development of Type I and Type II small molecule inhibitors based on structural understanding.
  • Insights into binding modes, inhibition mechanisms, and resistance.
  • Correlation between structural features and drug efficacy.

Conclusions:

  • Structural and conformational analysis is vital for designing effective VEGFR-2 inhibitors.
  • Strategies for improving inhibitor selectivity and activity are informed by molecular insights.
  • Further development can lead to novel anti-angiogenic drugs with enhanced therapeutic potential.

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...